Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Perspective Therapeutics. The associated price target is $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Burns has given his Buy rating due to a combination of factors including the ongoing dose escalation for Perspective Therapeutics’ VMT01, which is currently in a Phase 1/2a trial for metastatic melanoma. The trial has shown promising preliminary anti-tumor activity, and the Safety Monitoring Committee has approved a higher dose for further testing.
Furthermore, Burns highlights upcoming catalysts such as the presentation of clinical data updates at ESMO 2025, which could positively impact the stock. The valuation is supported by a discounted cash flow analysis, projecting a market value of $775 million and a 12-month price target of $10 per share. Despite potential risks like negative clinical outcomes and regulatory delays, the overall outlook remains optimistic, justifying the Buy rating.
In another report released on September 15, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.